Conclusion
sigmoid colon, rectosigmoid cancer
RECTAL CANCER, SILS
In conclusion, we found no significant difference in 3-year DFS and 5-year OS of patients with sigmoid colon and upper rectal cancer treated with SILS + 1 vs. CLS by experienced surgeons. Together with our previous reported short-term outcomes, these long-term oncologic outcomes of SILS + 1 support the adoption of this procedure as an alternative treatment for CLS in rectosigmoid cancer. It might be more practical to apply SILS + 1 over pure SILS.